News

Under the agreement, Mindray has acquired Datascope’s patient monitoring device business for a total purchase price of $209 million in cash, as adjusted for working capital at the

Terguride is currently being evaluated for pulmonary arterial hypertension (PAH) in a pivotal Phase II trial in Europe. Rudolf Reiter, CEO of Ergonex Pharma, said: “The FDA’s grant

This is claimed to be the longest duration of sustained neutralizing antibody levels observed against both virus types 16 and 18 with a cervical cancer vaccine to date.

Baruch Elad, chairman of the Israeli Society for Sleep Research at the Israel Medical Association, said: “Provigil is activated approximately 8-12 hours after medicine intake. It helps maintain

The study, COR-0002 trial, is a single-blind, open-label, single-center, cross-over pilot study where subjects underwent coronary balloon occlusion, with and without oxygenated HBOC-201. The primary objective of the

As announced earlier, shareholders of Hunter-Fleming now hold 3.1% in Newron. Italy based Newron Pharmaceuticals is a biopharmaceutical company focused on novel therapies for diseases of the central

The double-blind, placebo-controlled G301 study has examined the safety and efficacy of Pollinex Quattro in the treatment of seasonal allergic rhino-conjunctivitis (SAR) caused by grass pollen. The study

Under the agreement, Chugai will co-develop the compound with Taisho and co-market it with Taisho Toyama Pharmaceutical, a subsidiary of Taisho. Chugai will receive an upfront fee and

R7128 is being developed through the company’s collaboration with Roche. The purpose of this four-week study is to evaluate the safety, tolerability, pharmacokinetics and antiviral activity of R7128